Overview

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects with Type 2 diabetes mellitus (T2DM) following oral administration of Saxagliptin and Metformin XR fixed dose combination tablet and co-administration of Saxagliptin and Glucophage® (Metformin) IR tablets
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Metformin
Saxagliptin